A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy Infants
Probiotics are considered safe and beneficial to human health. However, the safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 in infants has not been confirmed. This study was to assess the safety of long-term oral administration of <...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Nutrients |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6643/15/15/3426 |
| _version_ | 1797586190961999872 |
|---|---|
| author | Jui-Fen Chen Mei-Chen Ou-Yang Ko-Chiang Hsia Neonatal Probiotic Use and Safety Research Group Ching-Min Li Yao-Tsung Yeh Hsieh-Hsun Ho |
| author_facet | Jui-Fen Chen Mei-Chen Ou-Yang Ko-Chiang Hsia Neonatal Probiotic Use and Safety Research Group Ching-Min Li Yao-Tsung Yeh Hsieh-Hsun Ho |
| author_sort | Jui-Fen Chen |
| collection | DOAJ |
| description | Probiotics are considered safe and beneficial to human health. However, the safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 in infants has not been confirmed. This study was to assess the safety of long-term oral administration of <i>L. salivarius</i> AP-32 and <i>B. animalis</i> CP-9 in healthy infants compared with placebo. A three-arm, randomized, double-blind, placebo-controlled trial was conducted in healthy, full-term infants. Eighty-eight infants between 7 days and 2 months (60 ± 7 days) of age were selected and randomized to treatment with <i>L. salivarius</i> AP-32, <i>B. animalis</i> CP-9 or placebo for 4 months. The unblinding indicated subjects were randomized to receive <i>B. animalis</i> CP-9 (N = 28), <i>L. salivarius</i> AP-32 (N = 29), or placebo (N = 31). A total of 76 infants completed the 4-month treatment with fully compliance. The primary outcome was weight gain, with no significant difference in infant weight at 4 months when comparing AP-32 or CP-9 group with the placebo group, either. The head circumference and recumbent length of the CP-9 group were not significantly different from those of the placebo group. The recumbent length of the AP-32 group was slightly lower than that in the placebo group at month 4, but there was no difference between the two groups in head circumference. Overall, the growth trend of all treatments was similar without significant difference. Furthermore, there were no apparent differences between each group in digestive tolerance, the occurrence of adverse events, crying/fussing time and episodes, alpha diversity, and beta diversity. The CP-9 group showed a significant increase in the abundance of the <i>Bacteroides</i> genus, while the AP-32 group demonstrated a significant increase in the abundance of the <i>Lactobacillus</i> genus when comparing the two probiotic groups. Our study findings indicate that the oral administration of both AP-32 and CP-9 strains has a positive impact on the maintenance of a healthy gut flora in infants. Long-term use of <i>L. salivarius</i> AP-32 or <i>B. animalis</i> CP-9 is safe for infants from 7 days to 6 months of age. |
| first_indexed | 2024-03-11T00:19:56Z |
| format | Article |
| id | doaj.art-cc05d391409a4853ae00b2ad062f6c84 |
| institution | Directory Open Access Journal |
| issn | 2072-6643 |
| language | English |
| last_indexed | 2024-03-11T00:19:56Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nutrients |
| spelling | doaj.art-cc05d391409a4853ae00b2ad062f6c842023-11-18T23:24:26ZengMDPI AGNutrients2072-66432023-08-011515342610.3390/nu15153426A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy InfantsJui-Fen Chen0Mei-Chen Ou-Yang1Ko-Chiang Hsia2Neonatal Probiotic Use and Safety Research Group3Ching-Min Li4Yao-Tsung Yeh5Hsieh-Hsun Ho6Department of Research and Design, Glac Biotech Co., Ltd., Tainan 744, TaiwanDepartment of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDepartment of Research and Design, Glac Biotech Co., Ltd., Tainan 744, TaiwanChang Gung Memorial Hospital, Taoyuan 333, TaiwanDepartment of Research and Design, Glac Biotech Co., Ltd., Tainan 744, TaiwanAging and Disease Prevention Research Center, Fooyin University, Kaohsiung 831, TaiwanDepartment of Research and Design, Glac Biotech Co., Ltd., Tainan 744, TaiwanProbiotics are considered safe and beneficial to human health. However, the safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 in infants has not been confirmed. This study was to assess the safety of long-term oral administration of <i>L. salivarius</i> AP-32 and <i>B. animalis</i> CP-9 in healthy infants compared with placebo. A three-arm, randomized, double-blind, placebo-controlled trial was conducted in healthy, full-term infants. Eighty-eight infants between 7 days and 2 months (60 ± 7 days) of age were selected and randomized to treatment with <i>L. salivarius</i> AP-32, <i>B. animalis</i> CP-9 or placebo for 4 months. The unblinding indicated subjects were randomized to receive <i>B. animalis</i> CP-9 (N = 28), <i>L. salivarius</i> AP-32 (N = 29), or placebo (N = 31). A total of 76 infants completed the 4-month treatment with fully compliance. The primary outcome was weight gain, with no significant difference in infant weight at 4 months when comparing AP-32 or CP-9 group with the placebo group, either. The head circumference and recumbent length of the CP-9 group were not significantly different from those of the placebo group. The recumbent length of the AP-32 group was slightly lower than that in the placebo group at month 4, but there was no difference between the two groups in head circumference. Overall, the growth trend of all treatments was similar without significant difference. Furthermore, there were no apparent differences between each group in digestive tolerance, the occurrence of adverse events, crying/fussing time and episodes, alpha diversity, and beta diversity. The CP-9 group showed a significant increase in the abundance of the <i>Bacteroides</i> genus, while the AP-32 group demonstrated a significant increase in the abundance of the <i>Lactobacillus</i> genus when comparing the two probiotic groups. Our study findings indicate that the oral administration of both AP-32 and CP-9 strains has a positive impact on the maintenance of a healthy gut flora in infants. Long-term use of <i>L. salivarius</i> AP-32 or <i>B. animalis</i> CP-9 is safe for infants from 7 days to 6 months of age.https://www.mdpi.com/2072-6643/15/15/3426probioticssafety<i>Lactobacillus salivarius</i><i>Bifidobacterium animalis</i> |
| spellingShingle | Jui-Fen Chen Mei-Chen Ou-Yang Ko-Chiang Hsia Neonatal Probiotic Use and Safety Research Group Ching-Min Li Yao-Tsung Yeh Hsieh-Hsun Ho A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy Infants Nutrients probiotics safety <i>Lactobacillus salivarius</i> <i>Bifidobacterium animalis</i> |
| title | A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy Infants |
| title_full | A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy Infants |
| title_fullStr | A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy Infants |
| title_full_unstemmed | A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy Infants |
| title_short | A Three-Arm, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of <i>Lactobacillus salivarius</i> AP-32 and <i>Bifidobacterium animalis</i> CP-9 Used Individually in Healthy Infants |
| title_sort | three arm randomized double blind placebo controlled study to evaluate the safety of i lactobacillus salivarius i ap 32 and i bifidobacterium animalis i cp 9 used individually in healthy infants |
| topic | probiotics safety <i>Lactobacillus salivarius</i> <i>Bifidobacterium animalis</i> |
| url | https://www.mdpi.com/2072-6643/15/15/3426 |
| work_keys_str_mv | AT juifenchen athreearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT meichenouyang athreearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT kochianghsia athreearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT neonatalprobioticuseandsafetyresearchgroup athreearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT chingminli athreearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT yaotsungyeh athreearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT hsiehhsunho athreearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT juifenchen threearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT meichenouyang threearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT kochianghsia threearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT neonatalprobioticuseandsafetyresearchgroup threearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT chingminli threearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT yaotsungyeh threearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants AT hsiehhsunho threearmrandomizeddoubleblindplacebocontrolledstudytoevaluatethesafetyofilactobacillussalivariusiap32andibifidobacteriumanimalisicp9usedindividuallyinhealthyinfants |